Serologicals' Upstate Group Announces Five Finalists for the 2006 Young Cell Signaller Award; Winner to be chosen June 13, 2006
2006年5月17日 - 9:00PM
ビジネスワイヤ(英語)
Serologicals Corporation (NASDAQ: SERO) today announced that five
finalists from 83 entries have been chosen for its Upstate Group
2006 Young Cell Signaller Award. Entries were submitted as
abstracts by Ph.D. students and first time post-doctorates
competing to win $17,000 worth of support funding for their
laboratory's reagents, a personal cash prize of $8,500 and a
trophy. The finalists will present their work on Tuesday, June 13th
in the morning for judging by an experienced scientific panel to
include two of the world's most cited scientists, Sir Philip Cohen
and Professor Doreen Cantrell. Each entrant will give a 25 - 30
minute presentation, followed by a five-minute question and answer
period. The winner will be announced at the conference dinner on
Tuesday, June 13th in the evening. The finalists and their
presentations are: Rashu Bhargava Seth, from the UT Southwestern
Medical Center, presenting "Understanding Host Antiviral Signaling
Pathways." Marzena Bienko, from the John Wolfgang Goethe
University, Frankfurt, presenting "Novel Ubiquitin-Binding Domains
in Y-Family Polymerases Regulate Translesion Synthesis." Kate
Jeffrey, from the Garvan Institute of Medical Research, presenting
"PAC-1 Phosphatase: as key positive regulator of immune cell
function and inflammatory responses." Nina Jones, from the Samuel
Lunenfeld Research Institute, presenting "Nck Adaptors Link Nephrin
to the Actin Cytoskeleton of Kidney Podocytes." Omar Perez, from
the Stanford University School of Medicine, presenting "Activation
State Analysis in Single Cells: a systems biology approach to
understanding intracellular mechanisms." Serologicals Corporation
President and CEO David Dodd commented on the finalists, "These
young people represent the future of our industry in medical
research. I congratulate all of them and wish them continued
success in their future work." The Third Annual Cell Signalling
Symposium will be held June 11-14, 2006, at the Apex City Quay
Hotel, Dundee, U.K. It is co-sponsored by Upstate and the MRC
Protein Phosphorylation Unit at the University of Dundee. The focus
for this three day, not-for-profit meeting is 'Signalling in the
Innate and Adaptive Immune Systems'. Registration is open to all
scientists with an interest in cell signalling, drug discovery and
disease. For more about the symposium or to register, visit
www.upstate.com/symposia/2006, call +44 (0) 1382 561600 or e-mail
registration@upstate.com. Upstate is a leading research discovery
provider of the highest quality cell signaling products and
services to the life science market. Its customers are biomedical
researchers at drug discovery companies and academic institutions
in the key disciplines of oncology, immunology, proteomics,
cardiology and neurology. Known for its enabling, innovative
solutions to help understand the biology of kinases, chromatin,
g-proteins and cytokines, Upstate's advanced cell biology tools -
drug screening services, enzymes, state specific antibodies, siRNA
kits, multiplex assays are used by thousands of customers
worldwide, every day to accelerate improving human health. Upstate,
a Serologicals company, is headquartered in Temecula, California,
and offices in Dundee, Scotland. For more information, please visit
our website www.upstate.com. Serologicals Corporation (NASDAQ:
SERO), headquartered in Atlanta, GA, is a global leader in
developing and commercializing consumable biological products,
enabling technologies and services in support of biological
research, drug discovery, and the bioprocessing of life-enhancing
products. Serologicals' customers include researchers at major life
science companies and leading research institutions involved in key
disciplines, such as neurology, oncology, hematology, immunology,
cardiology, proteomics, infectious diseases, cell signaling and
stem cell research. In addition, Serologicals is the world's
leading provider of monoclonal antibodies for the blood typing
industry. Serologicals employs approximately 1,000 people worldwide
and reported revenues of $275 million in 2005. For more
information, please visit our website: www.serologicals.com This
release contains certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words or phrases such as "should result," "are expected to," "we
anticipate," "we estimate," "we project" and similar expressions
are intended to identify forward-looking statements. These
statements are subject to certain risks and uncertainties that
could cause actual results to differ materially from those
expressed in any forward-looking statements. These risks and
uncertainties include, without limitation, our ability to continue
to introduce new products at a rapid pace and the acceptance of
such products by our customers. Serologicals is a registered
trademark of Serologicals Royalty Company.
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 5 2024 まで 6 2024
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 6 2023 まで 6 2024